{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:28:28Z","timestamp":1793600908199,"version":"4.5.0"},"reference-count":259,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025294","name":"Research Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["JPND-2023-2"],"award-info":[{"award-number":["JPND-2023-2"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["21\/RC\/10294-P2"],"award-info":[{"award-number":["21\/RC\/10294-P2"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.neuroscience.2026.04.007","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:17:39Z","timestamp":1776467859000},"page":"73-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Neuronal vulnerability in Parkinson\u2019s disease: insights from murine \u03b1-synuclein pathology models"],"prefix":"10.1016","volume":"605","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-7495","authenticated-orcid":false,"given":"Ziba","family":"Asadpoordezaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-7794","authenticated-orcid":false,"given":"Jochen H.M.","family":"Prehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neuroscience.2026.04.007_b0005","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jnc.14808","article-title":"\u03b1-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities","volume":"150","author":"Alam","year":"2019","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0010","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1038\/s41598-025-94165-0","article-title":"Viral mediated \u03b1-synuclein overexpression results in greater transgene levels and \u03b1-synuclein overload in mice bearing kinase dead mutation of LRRK2","volume":"15","author":"Albanese","year":"2025","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/genes8020063","article-title":"AAV vector-mediated gene delivery to substantia nigra dopamine neurons: implications for gene therapy and disease models","volume":"8","author":"Albert","year":"2017","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2202-14-6","article-title":"Time course and progression of wild type \u03b1-Synuclein accumulation in a transgenic mouse model","volume":"14","author":"Amschl","year":"2013","journal-title":"BMC Neurosci."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.04.007_b0025","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41593-025-01910-9","article-title":"Sympathetic and parasympathetic subtypes of body-first Lewy body disease observed in postmortem tissue from prediagnostic individuals","volume":"28","author":"Andersen","year":"2025","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103817","article-title":"\u03b1-synuclein fibrils per se but not \u03b1-synuclein seeded aggregation causes mitochondrial dysfunction and cell death in human neurons","volume":"86","author":"Angelova","year":"2025","journal-title":"Redox Biol."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.04.007_b0035","doi-asserted-by":"crossref","first-page":"e2628","DOI":"10.1002\/brb3.2628","article-title":"Modeling Parkinson's disease-related symptoms in alpha-synuclein overexpressing mice","volume":"12","author":"Aniszewska","year":"2022","journal-title":"Brain Behav."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.04.007_b0040","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14453","article-title":"Prevalence and associations of self-reported sleep problems in a large sample of patients with Parkinson's disease","volume":"34","author":"Asadpoordezaki","year":"2025","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0045","article-title":"Gene therapy for Parkinson\u2019s disease: a new frontier in neurodegenerative diseases","volume":"5","author":"Asuku","year":"2025","journal-title":"Expl. Neuroprot. Ther."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0050","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41531-024-00735-w","article-title":"Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates","volume":"10","author":"Balzano","year":"2024","journal-title":"npj Parkinson's Dis."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener. Dis."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.04.007_b0060","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3233\/JPD-212733","article-title":"Vagus nerve and stomach synucleinopathy in Parkinson's disease, incidental lewy body disease, and normal elderly subjects: evidence against the \u201cbody-first\u201d hypothesis","volume":"11","author":"Beach","year":"2021","journal-title":"J. Parkinsons Dis."},{"issue":"10","key":"10.1016\/j.neuroscience.2026.04.007_b0065","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1002\/jnr.24927","article-title":"Visualization of early oligomeric \u03b1-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]\u03b1-syn transgenic mouse model","volume":"99","author":"Behere","year":"2021","journal-title":"J. Neurosci. Res."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b0070","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","article-title":"The function of \u03b1-synuclein","volume":"79","author":"Bendor","year":"2013","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13024-023-00683-8","article-title":"Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson\u2019s disease in rodent brains","volume":"18","author":"B\u00e9rard","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0080","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41531-025-01150-5","article-title":"A multi-dimensional view on the etiology of Parkinson\u2019s disease","volume":"11","author":"Bernhardt","year":"2025","journal-title":"npj Parkinson's Dis."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.04.007_b0085","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.4103\/1673-5374.371345","article-title":"\u03b1-Synuclein oligomers and fibrils: partners in crime in synucleinopathies","volume":"18","author":"Bigi","year":"2023","journal-title":"Neural Regen. Res."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b0090","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3233\/JPD-240207","article-title":"The AAV-\u03b1-synuclein model of parkinson's disease: an update","volume":"14","author":"Bj\u00f6rklund","year":"2024","journal-title":"J. Parkinsons Dis."},{"issue":"8","key":"10.1016\/j.neuroscience.2026.04.007_b0095","first-page":"2307","article-title":"A combined \u03b1-Synuclein\/Fibril (SynFib) model of parkinson-like synucleinopathy targeting the nigrostriatal dopamine system","volume":"12","author":"Bj\u00f6rklund","year":"2022","journal-title":"J. Parkin. Dis."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.expneurol.2017.10.002","article-title":"Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification","volume":"298","author":"Blesa","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0105","series-title":"\u03b1-Synuclein Fibril, Ribbon and Fibril-91 Amyloid Polymorphs Generation for Structural Studies. Protein Aggregation: Methods and Protocols, (A. S. Cieplak)","first-page":"345","author":"Bousset","year":"2023"},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b0110","first-page":"207","article-title":"The Mighty Mouse: the impact of rodents on advances in biomedical research","volume":"110","author":"Bryda","year":"2013","journal-title":"Mo. Med."},{"issue":"10","key":"10.1016\/j.neuroscience.2026.04.007_b0115","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/acn3.246","article-title":"Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease","volume":"2","author":"Buddhala","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.04.007_b0120","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/JPD-150642","article-title":"The synaptic function of \u03b1-synuclein","volume":"5","author":"Burr\u00e9","year":"2015","journal-title":"J. Parkinsons Dis."},{"issue":"43","key":"10.1016\/j.neuroscience.2026.04.007_b0125","doi-asserted-by":"crossref","first-page":"15227","DOI":"10.1523\/JNEUROSCI.3545-12.2012","article-title":"Systematic mutagenesis of \u03b1-synuclein reveals distinct sequence requirements for physiological and pathological activities","volume":"32","author":"Burr\u00e9","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0130","doi-asserted-by":"crossref","unstructured":"Butkovich, L., Houser, M., Chalermpalanupap, T., Porter-Stransky, K., Iannitelli, A., Boles, J., Lloyd, G., Coomes, A., et al. (2020). Transgenic mice expressing human alpha-synuclein in noradrenergic neurons develop locus coeruleus pathology and non-motor features of Parkinson\u2019s disease. bioRxiv, 857987. Doi: 10.1101\/857987.","DOI":"10.1101\/857987"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0135","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fnins.2018.00626","article-title":"\u03b1-Synuclein and noradrenergic modulation of immune cells in Parkinson's disease pathogenesis","volume":"12","author":"Butkovich","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0140","article-title":"Genetic variants in SNCA and the risk of sporadic Parkinson's disease and clinical outcomes: a review","volume":"2017","author":"Camp\u00ealo","year":"2017","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.expneurol.2012.11.007","article-title":"Expression of human E46K-mutated \u03b1-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment","volume":"240","author":"Cannon","year":"2013","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110675","article-title":"Synaptic vesicle binding of \u03b1-synuclein is modulated by \u03b2- and \u03b3-synucleins","volume":"39","author":"Carnazza","year":"2022","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.04.007_b0155","doi-asserted-by":"crossref","DOI":"10.4081\/ejh.2021.3310","article-title":"Distribution of \u03b1-synuclein in normal human jejunum and its relations with the chemosensory and neuroendocrine system","volume":"65","author":"Casini","year":"2021","journal-title":"Eur. J. Histochem."},{"issue":"9440","key":"10.1016\/j.neuroscience.2026.04.007_b0160","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"Alpha-synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b0165","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1523\/JNEUROSCI.0089-14.2015","article-title":"A53T human \u03b1-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration","volume":"35","author":"Chen","year":"2015","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","article-title":"A progressive mouse model of Parkinson's disease: the Thy1-aSyn (\u201cLine 61\u201d) mice","volume":"9","author":"Chesselet","year":"2012","journal-title":"Neurotherapeutics"},{"issue":"9","key":"10.1016\/j.neuroscience.2026.04.007_b0175","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41593-022-01140-3","article-title":"Pathological structural conversion of \u03b1-synuclein at the mitochondria induces neuronal toxicity","volume":"25","author":"Choi","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0180","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.addr.2021.01.017","article-title":"Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic\/pharmacodynamic (PK\/PD) models","volume":"170","author":"Chowdhury","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b0185","doi-asserted-by":"crossref","first-page":"139","DOI":"10.14802\/jmd.19046","article-title":"Modeling \u03b1-synuclein propagation with preformed fibril injections","volume":"12","author":"Chung","year":"2019","journal-title":"J Mov Disord"},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0190","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/mds.21223","article-title":"The ups and downs of alpha-synuclein mRNA expression","volume":"22","author":"D\u00e4chsel","year":"2007","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0195","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00018-024-05419-5","article-title":"Lysosomal dysfunction in \u03b1-synuclein pathology: molecular mechanisms and therapeutic strategies","volume":"81","author":"Dai","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.100910","article-title":"\u03b1-Synuclein Translocates to the Nucleus to Activate Retinoic-Acid-Dependent Gene Transcription","volume":"23","author":"Davidi","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0205","series-title":"Nomenclature of Genetics, Mouse. Encyclopedia of Genetics, (S. Brenner & J. H. Miller)","first-page":"1336","author":"Davisson","year":"2001"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0210","doi-asserted-by":"crossref","unstructured":"Daynac, M., Mouilleau, V., Liu, Y., Yang, X., Shen, Y., & Guo, S. (2025). Scalable human cellular models of Parkinson's Disease reveal a druggable link between the angiotensin receptor 1 and \u03b1-synuclein pathology. bioRxiv. Doi: 10.1101\/2025.11.18.689137.","DOI":"10.1101\/2025.11.18.689137"},{"issue":"19","key":"10.1016\/j.neuroscience.2026.04.007_b0215","doi-asserted-by":"crossref","first-page":"E1817","DOI":"10.1073\/pnas.1305623110","article-title":"TFEB-mediated autophagy rescues midbrain dopamine neurons from \u03b1-synuclein toxicity","volume":"110","author":"Decressac","year":"2013","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b0220","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.neurol.2016.04.003","article-title":"Alpha-synuclein-based models of Parkinson's disease","volume":"172","author":"Dehay","year":"2016","journal-title":"Rev. Neurol."},{"issue":"2, Part 1","key":"10.1016\/j.neuroscience.2026.04.007_b0225","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.lpm.2017.01.001","article-title":"Epidemiology, environmental risk factors and genetics of Parkinson's disease","volume":"46","author":"Delamarre","year":"2017","journal-title":"La Presse M\u00e9dicale"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0230","article-title":"Lipopolysaccharide animal models of Parkinson's disease: recent progress and relevance to clinical disease","volume":"4","author":"Deng","year":"2020","journal-title":"Brain Behav. Immun. Health"},{"issue":"7","key":"10.1016\/j.neuroscience.2026.04.007_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001287","article-title":"\u03b1-Synuclein fibrils subvert lysosome structure and function for the propagation of protein misfolding between cells through tunneling nanotubes","volume":"19","author":"Dilsizoglu Senol","year":"2021","journal-title":"PLoS Biol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0240","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40035-023-00368-8","article-title":"Animal models of Parkinson\u2019s disease: bridging the gap between disease hallmarks and research questions","volume":"12","author":"Dovonou","year":"2023","journal-title":"Transl. Neurodegen."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0245","article-title":"Quality over quantity: advantages of using alpha-synuclein preformed fibril triggered synucleinopathy to model idiopathic Parkinson \u2019s disease [Perspective]","volume":"12\u20132018","author":"Duffy","year":"2018","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0250","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12974-018-1171-z","article-title":"Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration","volume":"15","author":"Duffy","year":"2018","journal-title":"J. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0255","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00401-016-1648-8","article-title":"Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology","volume":"133","author":"Dzamko","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0260","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12974-019-1636-8","article-title":"Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice","volume":"16","author":"Earls","year":"2019","journal-title":"J. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b0265","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.915","article-title":"Early fine motor impairment and behavioral dysfunction in (Thy-1)-h[A30P] alpha-synuclein mice","volume":"8","author":"Ekmark-Lew\u00e9n","year":"2018","journal-title":"Brain Behav."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0270","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41598-020-80889-8","article-title":"Human \u03b1-synuclein overexpression in a mouse model of Parkinson's disease leads to vascular pathology, blood brain barrier leakage and pericyte activation","volume":"11","author":"Elabi","year":"2021","journal-title":"Sci. Rep."},{"issue":"40","key":"10.1016\/j.neuroscience.2026.04.007_b0275","doi-asserted-by":"crossref","first-page":"35104","DOI":"10.1074\/jbc.M111.247965","article-title":"E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment","volume":"286","author":"Emmer","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.neuroscience.2026.04.007_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126389","article-title":"Adeno-associated viral vectors as versatile tools for parkinson's research, both for disease modeling purposes and for therapeutic uses","volume":"22","author":"Fajardo-Serrano","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0285","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41531-019-0103-7","article-title":"Parkinson's disease: proteinopathy or lipidopathy?","volume":"6","author":"Fanning","year":"2020","journal-title":"NPJ Parkinsons Dis."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b0290","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"14","author":"Fasano","year":"2015","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.04.007_b0295","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Feigin","year":"2017","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b0300","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tins.2025.04.005","article-title":"Neuromelanin and selective neuronal vulnerability to Parkinson\u2019s disease","volume":"48","author":"Filimontseva","year":"2025","journal-title":"Trends Neurosci."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b0305","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1602\/neurorx.2.3.495","article-title":"Genetic mouse models of Parkinsonism: strengths and limitations","volume":"2","author":"Fleming","year":"2005","journal-title":"NeuroRx"},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b0310","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11306-024-02181-4","article-title":"Dopaminergic neuron metabolism: relevance for understanding Parkinson's disease","volume":"20","author":"Flores-Ponce","year":"2024","journal-title":"Metabolomics"},{"issue":"9","key":"10.1016\/j.neuroscience.2026.04.007_b0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094643","article-title":"Genes implicated in familial parkinson's disease provide a dual picture of nigral dopaminergic neurodegeneration with mitochondria taking center stage","volume":"22","author":"Franco","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.04.007_b0320","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.neurobiolaging.2006.06.013","article-title":"Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice","volume":"28","author":"Freichel","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0325","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jchemneu.2016.02.001","article-title":"The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration","volume":"76","author":"Fu","year":"2016","journal-title":"J. Chem. Neuroanat."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0330","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"alpha-Synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell Biol."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.04.007_b0335","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12264-017-0170-x","article-title":"Olfactory dysfunction as an early biomarker in Parkinson's disease","volume":"33","author":"Fullard","year":"2017","journal-title":"Neurosci. Bull."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.04.007_b0340","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/nen.0b013e3180517454","article-title":"Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease","volume":"66","author":"Fumimura","year":"2007","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0345","doi-asserted-by":"crossref","unstructured":"Fushiki, A., Ng, D., Lewis, Z. R., Yadav, A., Saraiva, T., Hammond, L. A., Wirblich, C., Tasic, B., et al. (2024). A Vulnerable Subtype of Dopaminergic Neurons Drives Early Motor Deficits in Parkinson\u2019s Disease. bioRxiv, 2024.2012.2020.629776. Doi: 10.1101\/2024.12.20.629776.","DOI":"10.1101\/2024.12.20.629776"},{"issue":"7","key":"10.1016\/j.neuroscience.2026.04.007_b0350","first-page":"381","article-title":"Vulnerable dopamine neurons identified","volume":"18","author":"Fyfe","year":"2022","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b0355","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1289\/ehp.1003013","article-title":"Neuroinflammation and \u03b1-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease","volume":"119","author":"Gao","year":"2011","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2024.114959","article-title":"Viral overexpression of human alpha-synuclein in mouse substantia nigra dopamine neurons results in hyperdopaminergia but no neurodegeneration","volume":"382","author":"Garcia Moreno","year":"2024","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0365","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13024-020-00367-7","article-title":"PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease","volume":"15","author":"Ge","year":"2020","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0370","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13024-024-00756-2","article-title":"\u03b1-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease","volume":"19","author":"Geibl","year":"2024","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0375","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fneur.2018.00295","article-title":"Alpha-Synuclein: from Early Synaptic Dysfunction to Neurodegeneration","volume":"9","author":"Ghiglieri","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0380","article-title":"On cell loss and selective vulnerability of neuronal populations in Parkinson's disease [Review]","volume":"9\u20132018","author":"Gigu\u00e8re","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0385","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/B978-0-12-411512-5.00012-9","article-title":"Biomarkers, mechanisms, and potential prevention of catecholamine neuron loss in Parkinson disease","volume":"68","author":"Goldstein","year":"2013","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0390","article-title":"Modeling Parkinson\u2019s disease with the alpha-synuclein protein [review]","volume":"11\u20132020","author":"G\u00f3mez-Benito","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.neuroscience.2026.04.007_b0395","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/jnr.22331","article-title":"Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior","volume":"88","author":"Graham","year":"2010","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0400","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.nbd.2018.11.015","article-title":"P\u03b1-syn* mitotoxicity is linked to MAPK activation and involves tau phosphorylation and aggregation at the mitochondria","volume":"124","author":"Grassi","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.04.007_b0405","doi-asserted-by":"crossref","first-page":"E2634","DOI":"10.1073\/pnas.1713849115","article-title":"Identification of a highly neurotoxic \u03b1-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease","volume":"115","author":"Grassi","year":"2018","journal-title":"PNAS"},{"issue":"9","key":"10.1016\/j.neuroscience.2026.04.007_b0410","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1074\/jbc.M411638200","article-title":"The E46K mutation in alpha-synuclein increases amyloid fibril formation","volume":"280","author":"Greenbaum","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0415","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fncel.2016.00293","article-title":"Early degeneration of both dopaminergic and serotonergic axons - a common mechanism in Parkinson\u2019s disease","volume":"10","author":"Grosch","year":"2016","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0420","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","article-title":"Therapeutics in the pipeline targeting \u03b1-synuclein for Parkinson's disease","volume":"74","author":"Grosso Jasutkar","year":"2022","journal-title":"Pharmacol. Rev."},{"issue":"12","key":"10.1016\/j.neuroscience.2026.04.007_b0425","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00702-010-0509-1","article-title":"Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson\u2019s disease","volume":"117","author":"Gr\u00fcnblatt","year":"2010","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.crneur.2022.100065","article-title":"Characterisation of functional deficits induced by AAV overexpression of alpha-synuclein in rats","volume":"4","author":"Gubinelli","year":"2023","journal-title":"Curr. Res. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0435","doi-asserted-by":"crossref","unstructured":"Hadjas, L. C., Kollman, G. J., Linderhof, L., Xia, M., Mansur, S., Saint-Pierre, M., Lim, B. K., Lee, E. B., et al. (2025). Parkinson\u2019s Disease-vulnerable and -resilient dopamine neurons display opposite responses to excitatory input. bioRxiv, 2025.2006.2003.657460. Doi: 10.1101\/2025.06.03.657460.","DOI":"10.1101\/2025.06.03.657460"},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b0440","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4103\/1673-5374.202928","article-title":"Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator","volume":"12","author":"Haining","year":"2017","journal-title":"Neural Regen. Res."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0445","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.nbd.2012.04.009","article-title":"\u03b1-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits","volume":"47","author":"Hallett","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0450","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nbd.2013.04.017","article-title":"A novel \u03b1-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of \u03b1-synuclein-GFP","volume":"56","author":"Hansen","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0455","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s12035-020-02085-z","article-title":"A New Synuclein-Transgenic Mouse Model for Early Parkinson\u2019s reveals Molecular Features of Preclinical Disease","volume":"58","author":"Hendrickx","year":"2021","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0460","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40478-018-0541-1","article-title":"A53T-\u03b1-synuclein overexpression in murine locus coeruleus induces Parkinson\u2019s disease-like pathology in neurons and glia","volume":"6","author":"Henrich","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"issue":"12","key":"10.1016\/j.neuroscience.2026.04.007_b0465","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.18632\/aging.101691","article-title":"SNCA overexpression disturbs hippocampal gene expression trajectories in midlife","volume":"10","author":"Hentrich","year":"2018","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0470","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s40478-025-02093-x","article-title":"Evidence of a novel \u03b1-synuclein strain isolated from a Parkinson's disease with dementia patient sample","volume":"13","author":"Holec","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"issue":"12","key":"10.1016\/j.neuroscience.2026.04.007_b0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010956","article-title":"The E46K mutation modulates \u03b1-synuclein prion replication in transgenic mice","volume":"18","author":"Holec","year":"2022","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b0480","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.febslet.2011.01.009","article-title":"The role of the C-terminus of human \u03b1-synuclein: Intra-disulfide bonds between the C-terminus and other regions stabilize non-fibrillar monomeric isomers","volume":"585","author":"Hong","year":"2011","journal-title":"FEBS Lett."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.04.007_b0485","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/hmg\/ddz030","article-title":"GBA haploinsufficiency accelerates alpha-synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson\u2019s disease","volume":"28","author":"Ikuno","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105851","article-title":"Oxidative stress and synaptic dysfunction in rodent models of Parkinson's disease","volume":"173","author":"Imbriani","year":"2022","journal-title":"Neurobiol. Dis."},{"issue":"39","key":"10.1016\/j.neuroscience.2026.04.007_b0495","doi-asserted-by":"crossref","first-page":"E8274","DOI":"10.1073\/pnas.1703420114","article-title":"E46K \u03b1-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation","volume":"114","author":"\u00cd\u00f1igo-Marco","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0500","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40478-017-0416-x","article-title":"AAV1\/2-induced overexpression of A53T-\u03b1-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson\u2019s disease","volume":"5","author":"Ip","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0505","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13041-024-01104-7","article-title":"A novel mouse model for investigating \u03b1-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy","volume":"17","author":"Ishimoto","year":"2024","journal-title":"Mol. Brain"},{"issue":"5","key":"10.1016\/j.neuroscience.2026.04.007_b0510","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050785","article-title":"Various AAV serotypes and their applications in gene therapy: an overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2020.106507","article-title":"Biophysical processes underlying cross-seeding in amyloid aggregation and implications in amyloid pathology","volume":"269","author":"Ivanova","year":"2021","journal-title":"Biophys. Chem."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.04.007_b0520","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/mdc3.14068","article-title":"Parkinson's disease Associated with G2019S LRRK2 mutations without lewy body pathology","volume":"11","author":"Jackson","year":"2024","journal-title":"Mov. Disord. Clin Pract."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0525","article-title":"A case of Parkinson's disease with no lewy body pathology due to a homozygous exon deletion in Parkin","volume":"2018","author":"Johansen","year":"2018","journal-title":"Case Rep. Neurol. Med."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0530","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s42003-025-08138-0","article-title":"Structural and functional insights into the nuclear role of Parkinson\u2019s disease-associated \u03b1-synuclein as a histone chaperone","volume":"8","author":"Jos","year":"2025","journal-title":"Commun. Biol."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.04.007_b0535","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41593-022-01061-1","article-title":"Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease","volume":"25","author":"Kamath","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0540","article-title":"Intrastriatal administration of exosome-associated pathological alpha-synuclein is not sufficient by itself to cause pathology transmission [Original Research]","volume":"14\u20132020","author":"Karampetsou","year":"2020","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0545","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0170-23.2023","article-title":"Mice expressing A53T\/A30P mutant alpha-synuclein in dopamine neurons do not display behavioral deficits","volume":"11","author":"Keomanivong","year":"2024","journal-title":"Eneuro"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177419","article-title":"Dysregulation of serotonergic neurotransmission in Parkinson disease: a key duet","volume":"995","author":"Khowdiary","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0555","doi-asserted-by":"crossref","first-page":"17382","DOI":"10.1038\/s41598-019-54034-z","article-title":"Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinso\u0144s disease","volume":"9","author":"Kilpel\u00e4inen","year":"2019","journal-title":"Sci. Rep."},{"issue":"25","key":"10.1016\/j.neuroscience.2026.04.007_b0560","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu6050","article-title":"Differential pathological dynamics triggered by distinct Parkinson patient\u2013derived \u03b1-synuclein extracts in nonhuman primates","volume":"11","author":"Kinet","year":"2025","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.04.007_b0565","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1523\/JNEUROSCI.22-07-02780.2002","article-title":"Parkinson-like neurodegeneration induced by targeted overexpression of \u03b1-synuclein in the nigrostriatal system","volume":"22","author":"Kirik","year":"2002","journal-title":"J. Neurosci."},{"issue":"20","key":"10.1016\/j.neuroscience.2026.04.007_b0570","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/hmg\/ddl243","article-title":"Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity","volume":"15","author":"Kontopoulos","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.04.007_b0575","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrn.2017.75","article-title":"Animal models of \u03b1-synucleinopathy for Parkinson disease drug development","volume":"18","author":"Koprich","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0580","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1038\/s41467-019-11928-w","article-title":"Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease","volume":"10","author":"Krashia","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0585","article-title":"Spectrum of Non-Motor Symptoms in Parkinson's Disease","volume":"13","author":"Kumaresan","year":"2021","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.neuroscience.2026.04.007_b0590","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/hmg\/ddq038","article-title":"Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes","volume":"19","author":"Kuo","year":"2010","journal-title":"Hum. Mol. Genet."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.04.007_b0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011464","article-title":"A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice","volume":"5","author":"Kurz","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.neuroscience.2026.04.007_b0600","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/mds.29137","article-title":"Nigral neurons degenerating in Parkinson's disease express the angiotensin receptor type 1 gene","volume":"37","author":"Labandeira-Garcia","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0605","article-title":"Temporal evolution of Inflammation and Neurodegeneration with Alpha-Synuclein Propagation in Parkinson's disease mouse model [Original Research]","volume":"15\u20132021","author":"Lai","year":"2021","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0610","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbi.2025.04.025","article-title":"The basolateral amygdala and striatum propagate alpha-synuclein pathology causing increased fear response in a Parkinson\u2019s disease model","volume":"128","author":"Lai","year":"2025","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.04.007_b0615","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/acs.biochem.5b01168","article-title":"Stabilization of \u03b1-synuclein fibril clusters prevents fragmentation and reduces seeding activity and toxicity","volume":"55","author":"Lam","year":"2016","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.neuroscience.2026.04.007_b0620","doi-asserted-by":"crossref","DOI":"10.1042\/NS20210026","article-title":"Animal models of Parkinson's disease: a guide to selecting the optimal model for your research","volume":"5","author":"Lama","year":"2021","journal-title":"Neuronal. Signal"},{"issue":"4","key":"10.1016\/j.neuroscience.2026.04.007_b0625","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/ejn.13493","article-title":"Toxic effects of human and rodent variants of alpha-synuclein invivo","volume":"45","author":"Landeck","year":"2017","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0630","doi-asserted-by":"crossref","unstructured":"Lantheaume, A., Sch\u00f6neberg, N., Rodriguez-Rozada, S., Doll, D., Schellenberger, M., Kobel, K., Katzenberger, K., Signoret-Genest, J., et al. (2023). A viral vector model for circuit-specific synucleinopathy. bioRxiv, 2023.2008.2028.555129. Doi: 10.1101\/2023.08.28.555129.","DOI":"10.1101\/2023.08.28.555129"},{"issue":"11","key":"10.1016\/j.neuroscience.2026.04.007_b0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004741","article-title":"Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation","volume":"10","author":"L\u00e1zaro","year":"2014","journal-title":"PLoS Genet."},{"issue":"13","key":"10.1016\/j.neuroscience.2026.04.007_b0640","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1073\/pnas.132197599","article-title":"Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 \u2013> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice","volume":"99","author":"Lee","year":"2002","journal-title":"PNAS"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0645","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fnins.2019.00457","article-title":"Dysfunction of Cellular Proteostasis in Parkinson's Disease","volume":"13","author":"Lehtonen","year":"2019","journal-title":"Front. Neurosci."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.04.007_b0650","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.14336\/AD.2022.0216","article-title":"Decoding the role of familial parkinson's disease-related genes in DNA damage and repair","volume":"13","author":"Li","year":"2022","journal-title":"Aging Dis."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.04.007_b0655","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1172\/JCI72176","article-title":"Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation","volume":"124","author":"Liu","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2023.137555","article-title":"Distribution, connection and function of ALDH1A1+\/TH+ neurons in substantia nigra pars reticulata of mouse","volume":"818","author":"Liu","year":"2024","journal-title":"Neurosci. Lett."},{"issue":"16","key":"10.1016\/j.neuroscience.2026.04.007_b0665","doi-asserted-by":"crossref","first-page":"10813","DOI":"10.1073\/pnas.152339799","article-title":". α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's diseas","volume":"99","author":"Lo Bianco","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0670","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41531-023-00586-x","article-title":"Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson\u2019s disease patients","volume":"9","author":"L\u00f3pez-Aguirre","year":"2023","journal-title":"npj Parkinson's Dis."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0675","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.nbd.2011.12.038","article-title":"Use of viral vectors to create animal models for Parkinson's disease","volume":"48","author":"L\u00f6w","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"6109","key":"10.1016\/j.neuroscience.2026.04.007_b0680","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.neuroscience.2026.04.007_b0685","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1073\/pnas.1200575109","article-title":"Impaired neurotransmission caused by overexpression of \u03b1-synuclein in nigral dopamine neurons","volume":"109","author":"Lundblad","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b0690","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1460-9568.2012.08012.x","article-title":"Cognitive deficits in a mouse model of pre-manifest Parkinson's disease","volume":"35","author":"Magen","year":"2012","journal-title":"Eur. J. Neurosci."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.04.007_b0695","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3233\/JPD-150685","article-title":"The concept of prodromal Parkinson\u2019s disease","volume":"5","author":"Mahlknecht","year":"2015","journal-title":"J. Parkins. Dis."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.04.007_b0700","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1073\/pnas.1913904117","article-title":"The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration","volume":"117","author":"Mahul-Mellier","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b0705","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.nbd.2006.04.007","article-title":"Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression","volume":"23","author":"Maingay","year":"2006","journal-title":"Neurobiol. Dis."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.04.007_b0710","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/NEN.0b013e3181ac10a7","article-title":"Lewy body pathology in normal elderly subjects","volume":"68","author":"Markesbery","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0715","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s40478-021-01288-2","article-title":"Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro","volume":"9","author":"Marotta","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"issue":"5456","key":"10.1016\/j.neuroscience.2026.04.007_b0720","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0725","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nbd.2014.10.016","article-title":"Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits","volume":"74","author":"Masoud","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0730","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41531-024-00824-w","article-title":"Systemic inflammation accelerates neurodegeneration in a rat model of Parkinson\u2019s disease overexpressing human alpha synuclein","volume":"10","author":"Massaro Cenere","year":"2024","journal-title":"npj Parkinson's Dis."},{"issue":"Pt 4","key":"10.1016\/j.neuroscience.2026.04.007_b0735","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/brain\/awt037","article-title":"Prion-like spreading of pathological \u03b1-synuclein in brain","volume":"136","author":"Masuda-Suzukake","year":"2013","journal-title":"Brain"},{"issue":"15","key":"10.1016\/j.neuroscience.2026.04.007_b0740","doi-asserted-by":"crossref","first-page":"9412","DOI":"10.1074\/jbc.M114.610774","article-title":"Parkinson disease mutant E46K enhances \u03b1-synuclein phosphorylation in mammalian cell lines, in yeast, and in vivo","volume":"290","author":"Mbefo","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0745","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41598-023-49600-5","article-title":"Striatal dopamine neurotransmission is altered in age- and region-specific manner in a Parkinson\u2019s disease transgenic mouse","volume":"14","author":"Medina-Luque","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0750","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1478-811X-11-34","article-title":"Complexity of dopamine metabolism","volume":"11","author":"Meiser","year":"2013","journal-title":"Cell Commun. Signaling"},{"issue":"7","key":"10.1016\/j.neuroscience.2026.04.007_b0755","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/mdc3.70029","article-title":"The gut-brain axis in Parkinson disease: emerging Concepts and Therapeutic Implications","volume":"12","author":"Menozzi","year":"2025","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0760","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/978-94-007-5416-4_16","article-title":"Parkinson's disease","volume":"65","author":"Mhyre","year":"2012","journal-title":"Subcell. Biochem."},{"issue":"15","key":"10.1016\/j.neuroscience.2026.04.007_b0765","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/mds.22775","article-title":"Incidental Lewy body disease restricted to the heart and stellate ganglia","volume":"24","author":"Miki","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2023.114781","article-title":"Young human alpha synuclein transgenic (BAC-SNCA) mice display sex- and gene-dose-dependent phenotypic disturbances","volume":"460","author":"Moceri","year":"2024","journal-title":"Behav. Brain Res."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.04.007_b0775","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.neurobiolaging.2011.06.022","article-title":"Prion-like acceleration of a synucleinopathy in a transgenic mouse model","volume":"33","author":"Mougenot","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0780","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.neubiorev.2016.07.010","article-title":"Motor symptoms in Parkinson's disease: a unified framework","volume":"68","author":"Moustafa","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0785","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","article-title":"Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis","volume":"65","author":"Nemani","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0790","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.826193","article-title":"Evidence that substantia Nigra Pars compacta dopaminergic neurons are selectively vulnerable to oxidative stress because they are highly metabolically active","volume":"16","author":"Ni","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0795","article-title":"Clinical manifestations and molecular backgrounds of Parkinson's disease regarding genes identified from familial and population studies [Review]","volume":"13\u20132022","author":"Nishioka","year":"2022","journal-title":"Front. Neurol."},{"issue":"Pt 2","key":"10.1016\/j.neuroscience.2026.04.007_b0800","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/brain\/aws358","article-title":"A progressive dopaminergic phenotype associated with neurotoxic conversion of \u03b1-synuclein in BAC-transgenic rats","volume":"136","author":"Nuber","year":"2013","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0805","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2018.09.014","article-title":"Abrogating native & #x3b1;-synuclein tetramers in mice causes a L-DOPA-responsive motor syndrome closely resembling Parkinson\u2019s disease","volume":"100","author":"Nuber","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0810","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1326-8-44","article-title":"rAAV2\/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration","volume":"8","author":"Oliveras-Salv\u00e1","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0815","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.arr.2016.01.001","article-title":"(123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in \u03b1-synucleinopathies","volume":"30","author":"Orimo","year":"2016","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0820","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries\/territories from 1990 to 2019","volume":"9","author":"Ou","year":"2021","journal-title":"Front. Public Health"},{"issue":"18","key":"10.1016\/j.neuroscience.2026.04.007_b0825","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.cub.2015.07.050","article-title":"Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons","volume":"25","author":"Pacelli","year":"2015","journal-title":"Curr. Biol."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0830","article-title":"The noradrenergic system in Parkinson\u2019s disease [Review]","volume":"11\u20132020","author":"Paredes-Rodriguez","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104525","article-title":"Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal \u03b1-synuclein preformed fibrils","volume":"130","author":"Patterson","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0840","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41531-023-00620-y","article-title":"Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrils","volume":"10","author":"Patterson","year":"2024","journal-title":"npj Parkinson's Dis."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0845","article-title":"Generation of alpha-synuclein preformed fibrils from monomers and use in vivo","volume":"148","author":"Patterson","year":"2019","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0850","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nbd.2015.06.003","article-title":"Intrastriatal injection of pre-formed mouse \u03b1-synuclein fibrils into rats triggers \u03b1-synuclein pathology and bilateral nigrostriatal degeneration","volume":"82","author":"Paumier","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0855","doi-asserted-by":"crossref","unstructured":"Peat, C., Prasad, A., Finkelstein, D., Sue, C., Johnston, J. A., Parish, C. L., Thompson, L., Kirik, D., et al. (2025). Transgenic A53T mice have astrocytic \u03b1-synuclein aggregates in dopamine and striatal regions. bioRxiv, 2025.2001.2009.632283. Doi: 10.1101\/2025.01.09.632283.","DOI":"10.1101\/2025.01.09.632283"},{"issue":"7556","key":"10.1016\/j.neuroscience.2026.04.007_b0860","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature14547","article-title":"\u03b1-Synuclein strains cause distinct synucleinopathies after local and systemic administration","volume":"522","author":"Peelaerts","year":"2015","journal-title":"Nature"},{"issue":"7706","key":"10.1016\/j.neuroscience.2026.04.007_b0865","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-018-0104-4","article-title":"Cellular milieu imparts distinct pathological \u03b1-synuclein strains in \u03b1-synucleinopathies","volume":"557","author":"Peng","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120730","article-title":"Alpha-synuclein in skin as a high-quality biomarker for Parkinson's disease","volume":"451","author":"Peng","year":"2023","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0875","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1038\/s41598-017-06724-9","article-title":"Early synaptic dysfunction induced by \u03b1-synuclein in a rat model of Parkinson's disease","volume":"7","author":"Phan","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b0880","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ajpath.2013.09.002","article-title":"Mitochondrial abnormality associates with type-specific neuronal loss and cell morphology changes in the pedunculopontine nucleus in Parkinson disease","volume":"183","author":"Pienaar","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0885","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3233\/JPD-171248","article-title":"Best practices for generating and using alpha-synuclein pre-formed fibrils to model parkinson's disease in rodents","volume":"8","author":"Polinski","year":"2018","journal-title":"J. Parkinsons Dis."},{"issue":"5321","key":"10.1016\/j.neuroscience.2026.04.007_b0890","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0895","article-title":"Limitations of animal models of Parkinson's disease","volume":"2011","author":"Potashkin","year":"2010","journal-title":"Parkinsons Dis"},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b0900","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.70008","article-title":"Challenges and opportunities in exploring non-motor symptoms in 6-hydroxydopamine models of parkinson's disease: a systematic review","volume":"169","author":"Prates-Rodrigues","year":"2025","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0905","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.brainresbull.2019.05.024","article-title":"Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors","volume":"150","author":"Puhl","year":"2019","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2023.114645","article-title":"Role of dopamine neuron activity in Parkinson's disease pathophysiology","volume":"373","author":"Rademacher","year":"2024","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b0915","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","article-title":"Depletion of dopamine in Parkinson's disease and relevant therapeutic options: a review of the literature","volume":"10","author":"Ramesh","year":"2023","journal-title":"AIMS Neurosci."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105798","article-title":"Age-dependent neurodegeneration and neuroinflammation in a genetic A30P\/A53T double-mutated \u03b1-synuclein mouse model of Parkinson's disease","volume":"171","author":"Rauschenberger","year":"2022","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b0925","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ana.24066","article-title":"Lewy body extracts from Parkinson disease brains trigger \u03b1-synuclein pathology and neurodegeneration in mice and monkeys","volume":"75","author":"Recasens","year":"2014","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0930","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00401-017-1792-9","article-title":"Spread of aggregates after olfactory bulb injection of \u03b1-synuclein fibrils is associated with early neuronal loss and is reduced long term","volume":"135","author":"Rey","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.04.007_b0935","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1084\/jem.20160368","article-title":"Widespread transneuronal propagation of \u03b1-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease","volume":"213","author":"Rey","year":"2016","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0940","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40478-021-01136-3","article-title":"Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson's disease","volume":"9","author":"Reyes","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0945","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/exnr.2002.7882","article-title":"Behavioral and neurochemical effects of wild-type and mutated human \u03b1-synuclein in transgenic mice","volume":"175","author":"Richfield","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0950","series-title":"StatPearls [Internet]","article-title":"Lewy Bodies","author":"Rocha Cabrero","year":"2023"},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b0955","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3233\/JPD-213007","article-title":"Prevalence of prodromal symptoms of Parkinson's disease in the late middle-aged population","volume":"12","author":"Roos","year":"2022","journal-title":"J. Parkinsons Dis."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.04.007_b0960","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00702-019-02074-0","article-title":"Hyposmia as a marker of (non-)motor disease severity in Parkinson\u2019s disease","volume":"126","author":"Roos","year":"2019","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0965","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neurobiolaging.2021.01.010","article-title":"Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice","volume":"101","author":"Roshanbin","year":"2021","journal-title":"Neurobiol. Aging"},{"issue":"16","key":"10.1016\/j.neuroscience.2026.04.007_b0970","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1523\/JNEUROSCI.1478-20.2021","article-title":"REST protects dopaminergic neurons from mitochondrial and \u03b1-synuclein oligomer pathology in an alpha synuclein overexpressing BAC-transgenic mouse model","volume":"41","author":"Ryan","year":"2021","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0975","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12889-023-15018-x","article-title":"The burden of Parkinson's disease in the Middle East and North Africa region, 1990-2019: results from the global burden of disease study 2019","volume":"23","author":"Safiri","year":"2023","journal-title":"BMC Public Health"},{"key":"10.1016\/j.neuroscience.2026.04.007_b0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2024.114887","article-title":"\u237a-Synuclein levels in Parkinson's disease \u2013 Cell types and forms that contribute to pathogenesis","volume":"379","author":"Sagredo","year":"2024","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0985","article-title":"Nigrostriatal dopaminergic vulnerability in Parkinson's disease: neuroprotective strategies","author":"Santana-Rom\u00e1n","year":"2025","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neuroscience.2026.04.007_b0990","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-015-0046-9","article-title":"No apparent transmission of transgenic \u03b1-synuclein into nigrostriatal dopaminergic neurons in multiple mouse models","volume":"4","author":"Sastry","year":"2015","journal-title":"Transl. Neurodegener."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b0995","doi-asserted-by":"crossref","first-page":"10919","DOI":"10.1038\/s41598-019-47227-z","article-title":"Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders","volume":"9","author":"Schaser","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2026.04.007_b1000","doi-asserted-by":"crossref","unstructured":"Sciortino, A., Hentrich, T., Helgueta, S., Garcia, P., Schmit, K. J., Thomas, M. H., Halder, R., Coowar, D., et al. (2025). Transcriptional Dysregulation in the Hippocampus of a murine model for Parkinson\u2019s Disease Cognition Impairment is Driven by Sex, Age, and Alpha-synuclein overexpression. bioRxiv, 2025.2007.2018.665564. Doi: 10.1101\/2025.07.18.665564.","DOI":"10.1101\/2025.07.18.665564"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b1005","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1038\/s41598-019-41091-7","article-title":"Unbalanced calcium channel activity underlies selective vulnerability of nigrostriatal dopaminergic terminals in Parkinsonian mice","volume":"9","author":"Sgobio","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b1010","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1038\/s41598-017-05598-1","article-title":"Aldehyde dehydrogenase 1\u2013positive nigrostriatal dopaminergic fibers exhibit distinct projection pattern and dopamine release dynamics at mouse dorsal striatum","volume":"7","author":"Sgobio","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b1015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","article-title":"\u03b1-Synuclein in synaptic function and dysfunction","volume":"46","author":"Sharma","year":"2023","journal-title":"Trends Neurosci."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b1020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/ncb2131","article-title":"CSP\u03b1 promotes SNARE-complex assembly by chaperoning SNAP-25 during synaptic activity","volume":"13","author":"Sharma","year":"2011","journal-title":"Nat. Cell Biol."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b1025","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/WNR.0000000000002027","article-title":"Neuroprotective effect of green tea extract (-)-epigallocatechin-3-gallate in a preformed fibril-induced mouse model of Parkinson\u2019s disease","volume":"35","author":"Shen","year":"2024","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b1030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson disease epidemiology, pathology, genetics, and pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin. Geriatr. Med."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b1035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13024-023-00628-1","article-title":"Overexpression of human alpha-Synuclein leads to dysregulated microbiome\/metabolites with ageing in a rat model of Parkinson disease","volume":"18","author":"Singh","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"8","key":"10.1016\/j.neuroscience.2026.04.007_b1040","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/mds.29051","article-title":"Dopaminergic positron emission tomography imaging in the alpha-synuclein preformed fibril model reveals similarities to early Parkinson's disease","volume":"37","author":"Sossi","year":"2022","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.neuroscience.2026.04.007_b1045","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.neurobiolaging.2008.11.010","article-title":"Selective noradrenergic vulnerability in alpha-synuclein transgenic mice","volume":"31","author":"Sotiriou","year":"2010","journal-title":"Neurobiol. Aging"},{"issue":"6645","key":"10.1016\/j.neuroscience.2026.04.007_b1050","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.04.007_b1055","article-title":"Alpha-synuclein aggregation in Parkinson's disease","volume":"8","author":"Srinivasan","year":"2021","journal-title":"Front Med (lausanne)"},{"key":"10.1016\/j.neuroscience.2026.04.007_b1060","article-title":"Chemogenetic modulation of orexin neurons reverses changes in anxiety and locomotor activity in the A53T mouse model of parkinson\u2019s disease [Original Research]","volume":"13\u20132019","author":"Stanojlovic","year":"2019","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b1065","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI95795","article-title":"Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons","volume":"128","author":"Steinkellner","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuroscience.2026.04.007_b1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105804","article-title":"Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity","volume":"171","author":"Stoll","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2026.04.007_b1075","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.neuroscience.2026.04.007_b1080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048594","article-title":"HLA-DRB1 alleles are associated with the susceptibility to sporadic Parkinson\u2019s disease in chinese han population","volume":"7","author":"Sun","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06302","article-title":"Comparison of the expression and toxicity of AAV2\/9 carrying the human A53T \u03b1-synuclein gene in presence or absence of WPRE","volume":"7","author":"Sun","year":"2021","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b1090","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/cne.23901","article-title":"Brain region-dependent differential expression of alpha-synuclein","volume":"524","author":"Taguchi","year":"2016","journal-title":"J. Comp. Neurol."},{"issue":"8","key":"10.1016\/j.neuroscience.2026.04.007_b1095","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41582-022-00681-2","article-title":"The microbiome\u2013gut\u2013brain axis in Parkinson disease \u2014 from basic research to the clinic","volume":"18","author":"Tan","year":"2022","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b1100","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/biomedicines9030272","article-title":"A new rise of non-human primate models of synucleinopathies","volume":"9","author":"Teil","year":"2021","journal-title":"Biomedicines"},{"issue":"39","key":"10.1016\/j.neuroscience.2026.04.007_b1105","doi-asserted-by":"crossref","first-page":"E8284","DOI":"10.1073\/pnas.1710442114","article-title":"Modeling Parkinson\u2019s disease pathology by combination of fibril seeds and \u03b1-synuclein overexpression in the rat brain","volume":"114","author":"Thakur","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"15","key":"10.1016\/j.neuroscience.2026.04.007_b1110","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1523\/JNEUROSCI.4965-05.2006","article-title":"Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human \u03b1-synuclein(1\u2013120): implications for lewy body disorders","volume":"26","author":"Tofaris","year":"2006","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b1115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41531-020-0110-8","article-title":"Genetic predispositions of Parkinson\u2019s disease revealed in patient-derived brain cells","volume":"6","author":"Tran","year":"2020","journal-title":"npj Parkinson's Dis."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b1120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067506","article-title":"Genetic variations of GAK in two Chinese Parkinson\u2019s disease populations: a case-control study","volume":"8","author":"Tseng","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.neuroscience.2026.04.007_b1125","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson's disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b1130","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1038\/s41467-023-42705-5","article-title":"\u03b1-Synuclein aggregates amplified from patient-derived Lewy bodies recapitulate Lewy body diseases in mice","volume":"14","author":"Uemura","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.neuroscience.2026.04.007_b1135","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jnen\/nlz070","article-title":"Slow progressive accumulation of oligodendroglial alpha-synuclein (\u03b1-syn) pathology in synthetic \u03b1-syn fibril-induced mouse models of synucleinopathy","volume":"78","author":"Uemura","year":"2019","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuroscience.2026.04.007_b1140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0079-6123(10)84005-1","article-title":"Viral vector-mediated overexpression of \u03b1-synuclein as a progressive model of Parkinson's disease","volume":"184","author":"Ulusoy","year":"2010","journal-title":"Prog. Brain Res."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b1145","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","article-title":"The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies","volume":"139","author":"Van der Perren","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b1150","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.neurobiolaging.2014.11.015","article-title":"Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors","volume":"36","author":"Van der Perren","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2026.04.007_b1155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2015.03.046","article-title":"Rodent models for human diseases","volume":"759","author":"Vandamme","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b1160","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00429-025-02959-9","article-title":"Temporal progression of pathological features in an \u03b1-synuclein overexpression model of Parkinson\u2019s disease","volume":"230","author":"Vaquero-Rodr\u00edguez","year":"2025","journal-title":"Brain Struct. Funct."},{"issue":"10","key":"10.1016\/j.neuroscience.2026.04.007_b1165","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/mds.27776","article-title":"Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease","volume":"34","author":"Vila","year":"2019","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.04.007_b1170","doi-asserted-by":"crossref","first-page":"299","DOI":"10.37349\/ent.2023.00053","article-title":"Aldh1a1 and additional markers of dopamine cell heterogeneity in substantia nigra and ventral tegmental area identified as preserved in two transgenic \u03b1-synuclein mouse models of neurodegenerative disease","volume":"3","author":"Vlcek","year":"2023","journal-title":"Explor. Neuroprot. Ther."},{"key":"10.1016\/j.neuroscience.2026.04.007_b1175","doi-asserted-by":"crossref","unstructured":"Volpato, V., Menassa, D. A., Sheshadri, P., Giussani, S., Rokicki, M., Cardo, L. F., Bafaloukou, M., Schalkamp, A.-K., et al. (2025). A deep cellular atlas of the human ventral substantia nigra in Parkinson\u2019s identifies a genetic and molecular overlap with Type 2 Diabetes. medRxiv, 2025.2005.2028.25328401. Doi: 10.1101\/2025.05.28.25328401.","DOI":"10.1101\/2025.05.28.25328401"},{"issue":"S1","key":"10.1016\/j.neuroscience.2026.04.007_b1180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/jnc.13627","article-title":"How can rAAV-\u03b1-synuclein and the fibril \u03b1-synuclein models advance our understanding of Parkinson's disease?","volume":"139","author":"Volpicelli-Daley","year":"2016","journal-title":"J. Neurochem."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.04.007_b1185","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/nprot.2014.143","article-title":"Addition of exogenous \u03b1-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous \u03b1-synuclein to Lewy body and Lewy neurite-like aggregates","volume":"9","author":"Volpicelli-Daley","year":"2014","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b1190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.neuroscience.2026.04.007_b1195","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.neurobiolaging.2006.11.017","article-title":"Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice","volume":"29","author":"Wakamatsu","year":"2008","journal-title":"Neurobiol. Aging"},{"issue":"9","key":"10.1016\/j.neuroscience.2026.04.007_b1200","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1111\/j.1365-2982.2012.01974.x","article-title":"Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation","volume":"24","author":"Wang","year":"2012","journal-title":"Neurogastroenterol. Motil."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b1205","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi8287","article-title":"Molecular profiling of human substantia nigra identifies diverse neuron types associated with vulnerability in Parkinson\u2019s disease","volume":"10","author":"Wang","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.neuroscience.2026.04.007_b1210","article-title":"Studies on alpha-synuclein and islet amyloid polypeptide interaction [Original Research]","volume":"10\u20132023","author":"Wang","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.neuroscience.2026.04.007_b1215","article-title":"Viral vectors in neurodegenerative diseases: immune responses and therapeutic applications","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b1220","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.expneurol.2012.06.025","article-title":"Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein","volume":"237","author":"Watson","year":"2012","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b1225","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3233\/JPD-230129","article-title":"Alpha-synuclein pre-formed fibrils injected into prefrontal cortex primarily spread to cortical and subcortical structures","volume":"14","author":"Weber","year":"2024","journal-title":"J. Parkinsons Dis."},{"issue":"7, Part B","key":"10.1016\/j.neuroscience.2026.04.007_b1230","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.bbamem.2016.03.012","article-title":"Membrane remodeling and mechanics: experiments and simulations of \u03b1-synuclein","volume":"1858","author":"West","year":"2016","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Biomembr."},{"issue":"23","key":"10.1016\/j.neuroscience.2026.04.007_b1235","doi-asserted-by":"crossref","first-page":"15294","DOI":"10.3390\/ijms232315294","article-title":"Aggregated alpha-synuclein inclusions within the nucleus predict impending neuronal cell death in a mouse model of parkinsonism","volume":"23","author":"Weston","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.04.007_b1240","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3233\/JPD-240228","article-title":"Are preformed fibrils a model of Parkinson's disease?","volume":"14","author":"Woerman","year":"2024","journal-title":"J. Parkinsons Dis."},{"issue":"10","key":"10.1016\/j.neuroscience.2026.04.007_b1245","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/mds.27823","article-title":"Neuronal vulnerability in Parkinson disease: should the focus be on axons and synaptic terminals?","volume":"34","author":"Wong","year":"2019","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b1250","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.neures.2012.03.010","article-title":"\u03b1-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion","volume":"73","author":"Yamakado","year":"2012","journal-title":"Neurosci. Res."},{"issue":"s2","key":"10.1016\/j.neuroscience.2026.04.007_b1255","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.3233\/JPD-230393","article-title":"Experimental animal models of prodromal Parkinson's disease","volume":"14","author":"Yamakado","year":"2024","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b1260","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mds.29620","article-title":"Erythrocytic \u03b1-synuclein and the gut microbiome: kindling of the gut-brain axis in Parkinson's disease","volume":"39","author":"Yang","year":"2024","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b1265","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s12035-012-8327-0","article-title":"\u03b1-Synuclein and neuronal cell death","volume":"47","author":"Yasuda","year":"2013","journal-title":"Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.neuroscience.2026.04.007_b1270","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e21125","article-title":"Application of serum peptidomics for Parkinson's disease in SNCA-A30P mice","volume":"9","author":"Yin","year":"2023","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.neuroscience.2026.04.007_b1275","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s12276-022-00727-x","article-title":"Senescence and impaired DNA damage responses in alpha-synucleinopathy models","volume":"54","author":"Yoon","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.04.007_b1280","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archneur.60.3.337","article-title":"Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia Nigra in Alzheimer and Parkinson diseases","volume":"60","author":"Zarow","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuroscience.2026.04.007_b1285","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113768","article-title":"Progress in Parkinson's disease animal models of genetic defects: Characteristics and application","volume":"155","author":"Zhang","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.04.007_b1290","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41401-024-01428-z","article-title":"Progressive noradrenergic degeneration and motor cortical dysfunction in Parkinson\u2019s disease","volume":"46","author":"Zhou","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.04.007_b1295","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/iub.2654","article-title":"Neuromelanins in brain aging and Parkinson's disease: synthesis, structure, neuroinflammatory, and neurodegenerative role","volume":"75","author":"Zucca","year":"2023","journal-title":"IUBMB Life"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226002617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226002617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:48:33Z","timestamp":1793598513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226002617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":259,"alternative-id":["S0306452226002617"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.04.007","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuronal vulnerability in Parkinson\u2019s disease: insights from murine \u03b1-synuclein pathology models","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Brain Research Organization (IBRO).","name":"copyright","label":"Copyright"}]}}